URGN Stock Analysis: Buy, Sell, or Hold?
URGN - UroGen Pharma Ltd. Ordinary Shares
$34.88
-0.27 (-0.77%)
▼
5d:
+0.93%
30d:
-15.4%
90d:
-15.87%
BUY
MODERATE Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When URGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: URGN shows positive signals but monitor for confirmation. Market pricing in 13.2% decline. Moderate conviction.
💡 BUY OPPORTUNITY: URGN shows positive signals but monitor for confirmation. Market pricing in 13.2% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$75.40
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$46.82
25.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: URGN is currently trading at $34.88, which is considered oversold relative to its 30-day fair value range of $37.69 to $43.09. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.6) compared to its historical average (20.8). Remarkably, the market is currently pricing in an annual earnings decline of 13.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, URGN is in a strong uptrend. Immediate support is located at $33.40, while resistance sits at $39.09.
Market Sentiment: URGN scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $60.00 (+70.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, URGN is in a strong uptrend. Immediate support is located at $33.40, while resistance sits at $39.09.
Market Sentiment: URGN scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $60.00 (+70.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$37.69 -
$43.09
Company Quality Score
68/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 70.7% below Wall St target ($60.00)
- BULLISH: Bottoming setup score 68/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$37.69 -
$43.09
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$33.40
Resistance Level
$39.09
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.59
Wall Street Target
$60.00
(+70.7%)
Revenue Growth (YoY)
199.2%
Profit Margin
-51.7%
Valuation Discount vs History
-13.2% cheaper
PE vs Historical
13.6 vs 20.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.2%
(market-implied from PE analysis)
1-Year Target
$31.64
(-10%)
2-Year Target
$28.47
(-19%)
3-Year Target
$25.62
(-27%)
3-Yr Target (if PE normalizes)
(PE: 14→21)
$39.23
(+12%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.6 to 20.8
Stabilization Target:
$53.81
(+53.1%)
PE Expansion Potential:
+53.1%
Share & Embed Analysis
Last updated: October 23, 2026 10:50 AM ET
Data refreshes hourly during market hours. Next update: 11:50 AM
Data refreshes hourly during market hours. Next update: 11:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is URGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 77 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 49 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 60 HOLD |
Advanced URGN Option Strategies
Professional options setups generated by AI based on today's URGN price and gamma walls.
